TARGETING AGING
Our mission is to develop a pipeline of therapeutic assets that increase healthspan and lifespan.
Slowing aging and treating disease
Aging is the fundamental driver of many highly morbid, chronic diseases that reduce both the quantity and quality of life. We believe that intervening directly in the aging process will be the most impactful way to decrease the burden of disease and increase healthspan in an aging population.
Insights from human data
BioAge is mapping human aging from the ground up. We have forged partnerships with unique biobanks containing healthy human samples collected over decades that are paired with extensive follow-up records that include detailed future healthspan, lifespan, and disease outcomes. We are building deep molecular profiles of these samples, incorporating proteomics, metabolomics, and transcriptomics to identify the best drug targets for healthy aging.
BioAge Platform: from Target ID to Therapeutics
Our platform identifies key drug targets that will impact aging. The company’s proprietary human aging cohorts have blood samples collected up to 45 years ago, with participant -omics data that is tied to extensive medical follow-up records including detailed future healthspan, lifespan, and disease outcomes. We have built a systems biology and AI platform that leverages these rich datasets to identify the molecular drivers of age-related pathology. Our pipeline of therapies targeting these key pathways will address the significant unmet medical needs of an aging population.
Pipeline
BGE-117: BioAge’s first clinical-stage asset targets HIF signalling
A core longevity pathway that drives regeneration, healing, and resilience
The Hypoxia-inducible factor (HIF) pathway is linked to lifespan and healthspan in BioAge’s proprietary human aging data. Pathway activation levels are significantly associated with longevity and multiple functional measures. BGE-117 is a hypoxia-inducible factor-prolyl hydroxylase (HIF-PH) inhibitor that can potentially treat multiple diseases of aging through the activation of HIF-1 target genes that are involved in numerous biological processes including tissue regeneration, erythropoiesis, glycolysis, glucose uptake, vascular remodeling and angiogenesis.
BGE-175 INHIBITS PGD2 DP1 TO IMPROVE THE AGING IMMUNE SYSTEM
Potential to address multiple diseases where poor outcomes are driven by immune aging, including COVID-19, pandemic influenza, and beyond.
The molecular pathways impacted by BGE-175 are linked to lifespan and healthspan in BioAge’s proprietary human aging data. The prostaglandin pathway, as well as several key components of the immune response to viral challenge, are significantly associated with longevity and multiple functional measures. Inhibition of PGD2 DP1 receptor signaling impacts multiple immune mechanisms, including activation of dendritic cells and NK cells, and reducing neutrophil infiltration. Preclinical studies demonstrate that BGE-175 inhibits neutrophil migration and that DP1 inhibition boosts dendritic cell function, both of which counteract known aspects of immune aging, and are also therapeutically promising for COVID-19 and other respiratory infections. More details
BGE-175. DENDRITIC CELLS: IMPAIRED MIGRATION WITH AGING. NATURAL KILLER CELLS: REDUCED ACTIVITY WITH AGING. NEUTROPHILS: INCREASED INFILTRATION WITH AGING BGE-175. DENDRITIC CELLS: IMPAIRED MIGRATION WITH AGING. NATURAL KILLER CELLS: REDUCED ACTIVITY WITH AGING. NEUTROPHILS: INCREASED INFILTRATION WITH AGING
BGE-105 ACTIVATES APELIN/APJ SIGNALING TO TREAT MUSCLE AGING
A key pathway that promotes muscle regeneration and repair
Apelin is a small secreted peptide hormone that regulates multiple aspects of muscle physiology, including cell growth and survival, regeneration, and repair. BioAge’s analysis of our proprietary longitudinal aging data revealed that higher apelin signaling activity correlates with improved muscle function, reduced frailty, and longer lifespan. Apelin levels decline with age, and activation of apelin signaling reverses age-related sarcopenia in mice. BGE-105, an oral agonist of the apelin receptor APJ, could ameliorate muscle aging, which causes loss of strength, mobility, and function, driving mortality and multiple age-related diseases. By targeting this fundamental mechanism of aging, BGE-105 could treat multiple acute and chronic indications: improving muscle strength in frail patients, accelerating rehabilitation following fractures, and increasing mobility after extended bed rest. More details
BGE-105 ACTIVATES APELIN/APJ SIGNALING TO TREAT MUSCLE AGING BGE-105 ACTIVATES APELIN/APJ SIGNALING TO TREAT MUSCLE AGING
News
Leadership Team
Advisors
Board
Work with us
We believe that intervening directly in the aging process will be the most impactful way to decrease the burden of disease and increase healthspan in an aging population. We always look for talented individuals to join our mission. Check out our current job openings.
Contact us
Address: BioAge Labs, Inc., 1445A South 50th Street, Richmond, CA, 94804
General inquiries:
Media inquiries:
Business Development inquiries: